Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny has then
Immigrated to the United States, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published anumber of experimental research articles and theoretical articles as sole
Author. The abovementioned sole-author publications
Included two crucial themes.
The first of those discussed selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Validation their resistance. The outcomes and underlying
Notion were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the article was
Named, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author articles
Is a research method to produce knowledge by
Uniting a few facts together from seemingly unrelated fields.
This results in new concepts containing testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important result discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Inhibiting body aging — in other words, “preventing cancer
Via remainng young. ” His lab closely collaborated with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of additional anti-aging
Medications beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including several models such as
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Prolongation and cancer cure in mice, and combinations of anti-
Aging medicines to be used in humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.